 |
|
|
| |
Safety and Efficacy of 12 Weeks of Elbasvir (EBR)/Grazoprevir (GZR) in Hepatitis C Virus (HCV) GT1- and GT4-Infected Participants 65 Years and Older: An Integrated Analysis of Twelve Clinical Trials
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting 2017; Washington, DC, USA; October 20-24, 2017.
Steven L. Flamm1; Cheng-Yuan Peng2; Oren Shibolet3; Ronald Nahass4;
Peggy Hwang5; Eliav Barr5; Michael Robertson5; Barbara Haber5
1Northwestern University Feinberg School of Medicine, Chicago, IL, USA;
2China Medical University Hospital, Taichung City, Taiwan;
3Tel-Aviv Medical Center,Tel-Aviv, Israel; 4ID Care, Hillsborough, NJ, USA;
5Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
